Fox Run Management, L.L.C. Supernus Pharmaceuticals, Inc. Transaction History

Fox Run Management, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 17, 2019	SELL	$29.96 - $38.87 $480,378 - $623,241	-16,034 Closed	0 $0
Q1 2019 Oct 17, 2019	BUY	$32.77 - $41.99 $525,434 - $673,267	16,034 New	16,034 $562,000
Q2 2018 Jul 17, 2018	SELL	$44.1 - $59.85 $708,907 - $962,088	-16,075 Closed	0 $0
Q1 2018 Apr 17, 2018	SELL	$37.15 - $46.9 $219,185 - $276,710	-5,900 Reduced 26.85%	16,075 $736,000
Q4 2017 Jan 18, 2018	BUY	$36.4 - $42.6 $799,890 - $936,135	21,975	21,975 $876,000

286

60.7M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.14B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.